Skip to main content
PYC THERAPEUTICS LIMITED logo

PYC THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PYC ISIN · AU000000PYC7 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,297 across all filing types
Latest filing 2019-11-20 AGM Information
Country AU Australia
Listing ASX PYC

About PYC THERAPEUTICS LIMITED

https://pyctx.com/

PYC Therapeutics Limited is a clinical-stage company focused on developing precision medicines for patients with rare genetic diseases. The company utilizes a proprietary drug delivery platform that combines naturally derived cell-penetrating peptides with antisense oligonucleotides to create RNA-based therapeutics. This platform is designed to overcome the challenges of delivering large therapeutic molecules into target cells, particularly within the eye and central nervous system. PYC's primary pipeline includes VP-001, a candidate for Retinitis Pigmentosa type 11, and PYC-001, targeting Autosomal Dominant Optic Atrophy. Additionally, the company is advancing programs for Polycystic Kidney Disease. By leveraging its delivery technology, PYC aims to address the underlying genetic causes of diseases that currently lack effective treatment options.

Recent filings

Filing Released Lang Actions
2019 AGM Presentation 18 pages 909.1KB
AGM Information Classification · 95% confidence The document is titled 'PYC Annual General Meeting November 2019' and contains detailed presentation slides about the company's business, scientific progress, financial snapshot, shareholder information, and future milestones. It is structured as a presentation with visuals and bullet points, typical of materials shared during an Annual General Meeting (AGM). There is no indication of full financial statements or detailed annual report content, nor is it a brief announcement or regulatory filing. The content is consistent with AGM presentation materials intended to inform shareholders about company progress and strategy during the AGM event.
2019-11-20 English
2019 AGM Chairman's Address 3 pages 100.9KB
AGM Information Classification · 95% confidence The document is titled '2019 AGM Chairman’s Address' and is dated 21 November 2019. It contains a speech from the Chairman reflecting on the past year, company progress, future plans, and strategic direction. The content is typical of materials presented at an Annual General Meeting (AGM). There is no detailed financial data, audit information, or regulatory filing content. The document is about 5,186 characters, which is consistent with a presentation or address rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R).
2019-11-20 English
Results of 2019 Annual General Meeting 2 pages 85.9KB
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an ASX announcement dated 21 November 2019 reporting the results of the 2019 Annual General Meeting (AGM) of PYC Therapeutics Limited. It lists the voting outcomes for various resolutions including the Remuneration Report, election of directors, placement capacity, and company name change. The document is short (3105 characters) and focuses solely on the voting results of the AGM, without containing the full AGM materials or presentations. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). It is not the AGM presentation itself (AGM-R), nor an annual report or other financial report. Therefore, the correct classification is DVA with high confidence.
2019-11-20 English
Conclusion of Genentech Antimicrobial Collaboration 3 pages 244.8KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 15 November 2019 regarding the conclusion of a collaboration between PYC Therapeutics and Genentech on antimicrobial therapies. It provides background on the collaboration, scientific details about the peptide delivery, and the reason for the collaboration ending. There are no financial statements, no mention of quarterly or annual results, no voting results, no management changes, no fundraising or capital structure updates, and no regulatory certifications. The document is relatively short (3820 characters) and serves as a corporate update announcement about a project collaboration conclusion. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or others that require financial data or formal filings. It is a general regulatory announcement about a business development event. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous announcements that do not fit other specific categories.
2019-11-14 English
PYC Increases Shareholding in Vision Pharma 2 pages 81.2KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 14 November 2019 regarding PYC Therapeutics increasing its shareholding in Vision Pharma to 90%. It discusses the investment details, use of funds, and strategic implications. There are no financial statements, quarterly or annual results, or detailed financial data presented. The document is an announcement about a capital investment and shareholding increase, which fits the category of Capital/Financing Update. The document length is 3890 characters, which is relatively short but contains substantive information about financing activity, not just a report publication or a brief notice. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2019-11-13 English
Change in substantial holding 2 pages 95.8KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 604 under the Corporations Act 2001, which is a Notice of change of interests of a substantial holder. It details changes in voting power and relevant interests of a substantial shareholder in the company, including dates, nature of changes, and share quantities. This type of filing is a notification of changes in significant share ownership levels, which corresponds to the category of Major Shareholding Notification (MRQ). The document is not a financial report, earnings release, or management discussion, but a regulatory disclosure about shareholding changes.
2019-11-11 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.